title: AVP receptor antagonists in patients with CHF.
abstract: In the Adhere (Acute Decompensated Heart Failure Registry) National Registry, hyponatremia (serum sodium <130 mEq/l) at clinical presentation was noted in 5% of patients with HF. The enhanced release of arginine vasopressin (AVP) can lead to hyponatremia by binding to the V2 receptor results in free-water retention and hyponatremia. Given the central role of AVP in causing hyponatremia in patients with congestive heart failure, decreasing vasopressin activity has been a therapeutic focus. With no current therapy to decrease production of AVP, attention was turned to decreasing the effect of AVP by blocking the receptor.
authors.affiliation: Thomas Jefferson University Hospital, Jefferson Medical College, Philadelphia, PA, USA. drms1976@gmail.com
authors.forename: Siva K
authors.initials: SK
authors.lastname: Kumar
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Mather